Exuma Biotechnology

Executive Summary

Exuma Biotechnology is a private, clinical-stage company developing innovative gene vector delivery solutions and cell therapies to address key challenges in cell and gene therapy, such as complex manufacturing and the requirement for lymphodepleting chemotherapy. Founded in 2015 and headquartered in Coral Gables, Florida, the company focuses on both oncology and autoimmune diseases. Exuma's platform aims to improve patient access and therapeutic efficacy by simplifying production and reducing the need for pre-conditioning regimens. While the company is in Phase 1 development, its approach targets critical bottlenecks in the field, positioning it as a potential enabler of broader cell therapy adoption. With no disclosed financial data or public pipeline details, Exuma remains a preclinical/early clinical entity; however, its differentiated strategy could attract partnership interest from larger biopharma seeking next-generation delivery technologies.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Data Readout for Lead Oncology Candidate30% success
• Q2 2027IND Filing for Autoimmune Indication40% success
• Q3 2026Platform Proof-of-Concept Publication or Presentation50% success